Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

31.85USD
22 Jun 2018
Change (% chg)

$1.78 (+5.92%)
Prev Close
$30.07
Open
$30.18
Day's High
$31.95
Day's Low
$30.18
Volume
585,056
Avg. Vol
85,076
52-wk High
$35.52
52-wk Low
$16.98

Chart for

About

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocyt... (more)

Overall

Beta: --
Market Cap(Mil.): $714.42
Shares Outstanding(Mil.): 25.65
Dividend: --
Yield (%): --

Financials

  DOVA.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.92 -- --
ROI: -- 2.00 14.38
ROE: -- 3.49 16.08

BRIEF-Dova Pharmaceuticals Announces Proposed Offering Of Common Stock

* DOVA PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

20 Feb 2018

BRIEF-Dova Pharma Files For Offering Of Up To 2.5 Mln Shares

* DOVA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 2.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2FgTI9o) Further company coverage:

20 Feb 2018

BRIEF-Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​

* DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

15 Feb 2018

BRIEF-Dova Pharmaceuticals Announces Appointment Of Mark W. Hahn As Chief Financial Officer

* DOVA PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARK W. HAHN AS CHIEF FINANCIAL OFFICER

30 Jan 2018

BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018

* DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

03 Jan 2018

Earnings vs. Estimates